Searching News Database: Depomed
HSMN NewsFeed - 3 Nov 2015
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
HSMN NewsFeed - 15 Sep 2015
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
HSMN NewsFeed - 13 Apr 2015
Depomed Announces Gralise(R) ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
Depomed Announces Gralise(R) ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
HSMN NewsFeed - 28 May 2014
Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA
Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA
HSMN NewsFeed - 25 Jul 2013
Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer
Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
HSMN NewsFeed - 25 Mar 2010
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
HSMN NewsFeed - 10 Nov 2009
Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA(R)
Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA(R)
HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
HSMN NewsFeed - 25 Sep 2007
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
HSMN NewsFeed - 27 Aug 2007
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
HSMN NewsFeed - 12 Feb 2007
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
HSMN NewsFeed - 19 Oct 2006
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Additional items found! 34
Members Archive contains
34 additional stories matching:
Depomed
(Password required)
Depomed
(Password required)
